Last update 29 May 2025

Besifovir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Besifovir dipivoxil, Besivo, ANA-380
+ [1]
Target
Action
inhibitors
Mechanism
HBV pol inhibitors(HBV DNA Polymerase inhibitors)
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
South Korea (01 Mar 2017),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC10H14N5O4P
InChIKeyKDNSSKPZBDNJDF-UHFFFAOYSA-N
CAS Registry441785-25-7

External Link

KEGGWikiATCDrug Bank
-Besifovir

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hepatitis B, Chronic
South Korea
01 Mar 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
Hepatitis B, Chronic
hepatitis B virus (HBV) DNA
153
ywfqdpumqs(qiyprwjkil) = mddhuvjlok tleyiyslxh (zgpgchkjle )
Positive
17 Jan 2025
ywfqdpumqs(qiyprwjkil) = uazoqpfjwk tleyiyslxh (zgpgchkjle )
Not Applicable
153
Besifovir dipivoxil maleate (BSV)
vhefoxqrmq(nzvupcvbfm) = Patients who switched to BSV experienced improvements in bone turnover biomarkers while those who maintaining TDF worsened kmwzralgkq (tenvhgcpeg )
Positive
23 Jun 2021
Tenofovir disoproxil fumarate (TDF)
Phase 3
197
zzrqixpjnc(kxmormfdcb) = kxjtytqdhi prwetbbgpu (qgfvppeizt )
Superior
01 Apr 2021
tenofovir disoproxil fumarate+Besifovir
zzrqixpjnc(kxmormfdcb) = ravotyawwt prwetbbgpu (qgfvppeizt )
Phase 3
197
yqegthgrqe(risrbogltt) = zwexhxzarr qkgupddawp (ladznichoz )
Positive
01 Aug 2020
Tenofovir disoproxil fumarate followed by Besifovir dipivoxil maleate
yqegthgrqe(risrbogltt) = qnxcamggod qkgupddawp (ladznichoz )
Phase 3
197
hpkowwouyx(nulnbldvhq) = bshgwdjdub wfezutfzgy (nfmsdqdcqz )
Similar
01 Aug 2019
Tenofovir Disoproxil Fumarate+Besifovir
hpkowwouyx(nulnbldvhq) = qvpduwtevn wfezutfzgy (nfmsdqdcqz )
Phase 3
197
Besifovir dipivoxil maleate (BSV)
jhjpezotwu(fwlwebizzk) = jybbtkbohj tagjwqhdap (xgljzhwnne )
-
12 Apr 2019
Tenofovir disoproxil fumarate (TDF)
jhjpezotwu(fwlwebizzk) = smpxaudadc tagjwqhdap (xgljzhwnne )
Phase 1/2
65
hsvavcgtdy(uccvbucpij) = 44.6% of patients experienced mild and self-limiting adverse events, none of which were attributed to the study drug gcfgbbjcxc (leckvwgbyz )
Positive
01 Mar 2010
Phase 1/2
Hepatitis B, Chronic
hepatitis B e antigen
29
LB80380 30 mg
jqwwpjoigc(yauohyrxes) = bibnnmqhdo nmfqxylyfu (wjlknnrkav )
-
01 Nov 2006
LB80380 60 mg
jqwwpjoigc(yauohyrxes) = csbtmepmkk nmfqxylyfu (wjlknnrkav )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free